Eugenia Pareja

Hospital Universitario Dr. Peset
Valencia, VC, Spain

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 33 publications

The aryl hydrocarbon receptor is downregulated in MASLD while its activation attenuates steatosis in human hepatocytes through an IGFBP1-associated pathway.

The aryl hydrocarbon receptor is downregulated in MASLD while its activation attenuates steatosis in human hepatocytes through an IGFBP1-associated pathway.

Journal: Archives of toxicology

Published: May 14, 2026

The Development of a Non-Invasive Screening Method Based on Serum microRNAs to Quantify the Percentage of Liver Steatosis.

The Development of a Non-Invasive Screening Method Based on Serum microRNAs to Quantify the Percentage of Liver Steatosis.

Journal: Biomolecules

Published: October 08, 2024

Cluster-Partial Least Squares (c-PLS) regression analysis: Application to miRNA and metabolomic data.

Cluster-Partial Least Squares (c-PLS) regression analysis: Application to miRNA and metabolomic data.

Journal: Analytica chimica acta

Published: October 13, 2023

Comparing the direct assessment of steatosis in liver explants with mid- and near-infrared vibrational spectroscopy, prior to organ transplantation.

Comparing the direct assessment of steatosis in liver explants with mid- and near-infrared vibrational spectroscopy, prior to organ transplantation.

Journal: The Analyst

Published: August 04, 2023

Enhancing the accuracy of mid-infrared spectroscopy-based liver steatosis quantification using digital image analysis as a reference.

Enhancing the accuracy of mid-infrared spectroscopy-based liver steatosis quantification using digital image analysis as a reference.

Journal: The Analyst

Published: June 14, 2023

Gut Microbiota and Plasma Bile Acids Associated with Non-Alcoholic Fatty Liver Disease Resolution in Bariatric Surgery Patients.

Gut Microbiota and Plasma Bile Acids Associated with Non-Alcoholic Fatty Liver Disease Resolution in Bariatric Surgery Patients.

Journal: Nutrients

Published: May 24, 2023

A robust reprogramming strategy for generating hepatocyte-like cells usable in pharmaco-toxicological studies.

A robust reprogramming strategy for generating hepatocyte-like cells usable in pharmaco-toxicological studies.

Journal: Stem cell research & therapy

Published: September 21, 2022

Quantitative Prediction of Steatosis in Patients with Non-Alcoholic Fatty Liver by Means of Hepatic MicroRNAs Present in Serum and Correlating with Hepatic Fat.

Quantitative Prediction of Steatosis in Patients with Non-Alcoholic Fatty Liver by Means of Hepatic MicroRNAs Present in Serum and Correlating with Hepatic Fat.

Journal: International journal of molecular sciences

Published: July 04, 2022

Induced pluripotent stem cells for the treatment of liver diseases: challenges and perspectives from a clinical viewpoint.

Induced pluripotent stem cells for the treatment of liver diseases: challenges and perspectives from a clinical viewpoint.

Journal: Annals of translational medicine

Published: August 11, 2020

Improved in vivo efficacy of clinical-grade cryopreserved human hepatocytes in mice with acute liver failure.

Improved in vivo efficacy of clinical-grade cryopreserved human hepatocytes in mice with acute liver failure.

Journal: Cytotherapy

Published: October 22, 2019

Alternative Cell Sources to Adult Hepatocytes for Hepatic Cell Therapy.

Alternative Cell Sources to Adult Hepatocytes for Hepatic Cell Therapy.

Journal: Methods in molecular biology (Clifton, N.J.)

Published: November 11, 2016

Clinical Application of Pluripotent Stem Cells: An Alternative Cell-Based Therapy for Treating Liver Diseases?

Clinical Application of Pluripotent Stem Cells: An Alternative Cell-Based Therapy for Treating Liver Diseases?

Journal: Transplantation

Published: August 07, 2016

Showing 1-12 of 33

Last Updated: 09/26/2026